News Posted on July 28, 2026 ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial No ARIA-E observed across all genotypes, including APOE4 homozygotes Go to Source By sf-admin